Skip to content
Home/Companies/Biotechnology/HEPHAISTOS-Pharma
HEPHAISTOS-Pharma

HEPHAISTOS-Pharma

Biotechnology·France·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns HEPHAISTOS-Pharma?

HEPHAISTOS-Pharma is currently owned by Elaia Partners through DTS3 (2024 vintage), since 2024.

Hand-verified · updated 2026-04-21

Elaia Partners
Investor
Elaia Partners
DTS3 · 2024 · VC

Key facts

HQFrance
SectorBiotechnology
Websitehephaistos-pharma.fr

More from DTS3

Other portfolio companies in the same fund.

Enodia Therapeutics
Enodia Therapeutics
Active
BiotechFrance· 2026
GetVocal AI
Active
Data & AnalyticsFrance· 2025
Mimic Robotics
Active
IndustrialsUS· 2025
Proxima Fusion
Proxima Fusion
Active
ClimateTechGermany· 2025
Streambased
Active
Data & AnalyticsUK· 2025
Biophta
Biophta
Active
BiotechFrance· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track HEPHAISTOS-Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy HEPHAISTOS-Pharma?

0 strategic and 120financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on HEPHAISTOS-Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue